RGT

0.00%

30.0¢ argent biopharma limited

Thanks InX, for me a bit of a grey area with MC, but some great...

First 121 Last

Share
Profile

Follow
Owl vs Fox

6,434 Posts.

5274

22/10/18

16:10

Post #: 36213155
Share

Originally posted by InX_ ↑

Not quite.

Although naturally occurring products such as plants cannot be patented, formulations can be. For example, when pharmaceutical companies first thought of 'combining' 2 or more antihypertensive medications such as monopril PLUS hydrochlorothiazide into ONE, single tablet, they were able to patent these technically old drugs as 'new formulations'.

Another example was when the company that formulated Spiriva (tiotropium) came up with the Respimat device, despite already having the older, 'Handihaler' device. The company in this case was not able to patent the 'drug' per se, but was able to patent the overall medication due to its new formulation.

The relevance of all this relative to cannabis extracts is that there are ways for pharmaceutical companies to patent their products (despite not being able to patent the drugs/extract, themselves). A possible solution for medicinal cannabis companies to do this is by collaborating with medicinal chemists/drug-development/design pharmacists). These guys may come up with formulation ideas such as employing the use of cucurbiturils to allow formulations such as CannEpil 'target' endocannabinoid receptors, for example.

And finally, even if patenting was not possible, I have previously mentioned that what is relevant for clincians like myself is Evidence Based Medicine (EBM). We will always opt for whichever product has greater evidence backing its use and this often (but not always) means choosing older drugs on the market. Considering CannEpil is the second CBD formulation on the Australian market for human use, it ticks that box. Rest assured.

Anyway,
TL;DR
There are ways we're able to patent medicinal cannabis products but whether we do or don't does NOT matter.

InX_ (Consultant, Senior and Specialist Critical Care Pharmacist)

Expand

Thanks InX, for me a bit of a grey area with MC, but some great examples there & familiar with the Spiriva thing, it does become very technical & EBM definitely. Thank you for your post from an expert clinical pharmacological perspective.

MXC Price at posting: 6.6¢ Sentiment: Buy Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

EMD

Emyria's Empax Centre chosen for mental health clinical trial

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

STX

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

FHE

Frontier Energy achieves key milestone for Waroona energy project

BRX

Belararox delineates another porphyry in Argentina at Tambo South

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

There are more pages in this discussion • 142 more messages in this thread...

First 121 Last

Add RGT (ASX) to my watchlist

(20min delay)
Last 30.0¢		Change 0.000(0.00%)		Mkt cap ! $13.58M

Open	High	Low	Value	Volume
30.0¢	31.0¢	30.0¢	$2.567K	8.41K

Buyers (Bids)

No.	Vol.	Price($)
2	47481	30.0¢

Sellers (Offers)

Price($)	Vol.	No.
31.0¢	8026	2

View Market Depth

No.	Vol.	Price($)
2	47481	0.300
1	17426	0.275
1	15000	0.250
1	40820	0.245
1	18524	0.240

Price($)	Vol.	No.
0.310	8026	2
0.315	2876	1
0.320	2479	3
0.325	5304	1
0.330	2316	1

Last trade - 15.53pm 21/06/2024 (20 minute delay)

RGT (ASX) Chart

Thanks InX, for me a bit of a grey area with MC, but some great...

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Emyria's Empax Centre chosen for mental health clinical trial

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

Cultural heritage agreement puts Walford Creek exploration back on the map

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks InX, for me a bit of a grey area with MC, but some great...

Top Stories

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Emyria's Empax Centre chosen for mental health clinical trial

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Frontier Energy achieves key milestone for Waroona energy project

Belararox delineates another porphyry in Argentina at Tambo South

Cultural heritage agreement puts Walford Creek exploration back on the map

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News